GleamWall
中文EN

IRON Disc Medicine, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1816736 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-34.2%
TTM EPS YoY-18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.3%
ROA-36.6%
ROIC (approx.)-40.5%
Asset turnover—

Leverage & solvency

Liabilities / assets13.6%
Debt / equity0.10x
Current ratio20.30x
Interest coverage-61.10x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$170.64M$96.67M
SG&A expense$65.38M$33.05M
Operating income-$236.02M-$129.72M
Interest expense$3.61M$572,000
Pretax income-$211.82M-$109.00M
Income tax$361,000$355,000
Net income-$212.18M-$109.36M
EBITDA-$235.74M-$129.56M
EPS (basic)-6.01-3.96
EPS (diluted)-6.01-3.96
Weighted avg. shares (diluted)35.30M27.61M
Balance sheet
Cash & equivalents$91.14M$192.67M
Short-term investments$700.01M$297.45M
Current assets$803.90M$493.62M
PP&E, net$1.16M$751,000
Total assets$806.88M$496.77M
Current liabilities$36.64M$23.32M
Long-term debt$29.16M$28.32M
Total debt$29.16M$28.32M
Total liabilities$67.05M$53.19M
Shareholders' equity$739.83M$443.59M
Net debt-$61.99M-$164.35M
Shares outstanding37.89M29.87M
Cash flow statement
Operating cash flow-$180.39M-$93.93M
Capital expenditure$933,000$505,000
Free cash flow-$181.33M-$94.43M
Investing cash flow-$394.30M-$292.33M
Financing cash flow$473.41M$218.31M
Depreciation & amortization$281,000$156,000
Stock-based compensation$34.34M$16.82M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.